Skip to main content

Table 4 Ongoing phase 2 and 3 studies investigating late-line therapies in ovarian cancer

From: Bringing new medicines to women with epithelial ovarian cancer: what is the unmet medical need?

Agent NCT #
Study name
Phase Est. N Setting Expected completion
PARP Inhibitors
 Niraparib NCT02354586
QUADRA
2 400 Recurrent, ≥4th- 5th-line October 2017
 Olaparib NCT02282020
SOLO-3
3 411 Recurrent, ≥3rd-line December 2017
 Olaparib NCT02889900
CONCERTO
2 100 Recurrent, ≥3rd-line November 2018
 Rucaparib NCT01891344
ARIEL2
2 480 Recurrent, ≥4th-line March 2017
 Rucaparib NCT01968213
ARIEL3
3 540 Recurrent, ≥3rd-line March 2017
Mirvetuximab soravtansine (an antibody-drug conjugate targeting the folate-alpha receptor)
  NCT02631876
FORWARDI
3 333 Platinum-resistant; 1–3 prior lines of chemotherapy February 2019
NUC-1031 (gemcitabine prodruga)
  NCT03146663 2 64 Platinum-resistant; ≥3 prior lines of chemotherapy June 2020
Trabectedin (novel alkylating chemotherapy agent)
  NCT01846611
ORCHYD
3 670 Platinum-sensitive; 3rd line; known BRCA1/2 mutation December 2019
Ipilimumab (immune checkpoint inhibitor)
  NCT01611558 2 49 Platinum-sensitive; ≤4 prior lines of chemotherapy July 2019
Birinapant (SMAC mimetic and IAP inhibitor)
  NCT02756130 2 34 In combination with carboplatin in newly diagnosed or recurrent disease June 2020
Volasertib (Plk1 inhibitor)
     In development; no ongoing phase 2 or phase 3 studies  
  1. IAP inhibitor of apoptosis protein, Plk1 polo-like kinase 1, SMAC second mitochondrial-derived activator of caspases
  2. aProdrug is a compound that is metabolized into a pharmacologically active drug after administration